NEW YORK — Edgewise Therapeutics Inc. (NASDAQ: EWTX) shares surged more than 23% Tuesday morning, climbing to around $38.83 as investors piled into the clinical-stage biotech company amid growing optimism over its muscle disease pipeline and broader sector momentum.

The stock, which closed Monday near $31.45, jumped as much as 23.47% in early trading on elevated volume. The sharp move pushed Edgewise's market capitalization higher and marked one of the biggest percentage gains among Nasdaq-listed biotechs on the day.

Edgewise develops novel therapies for serious muscle disorders, including muscular dystrophies and certain cardiac conditions. Its lead candidate, sevasemten, targets skeletal muscle conditions like Becker muscular dystrophy, while EDG-7500 focuses on hypertrophic cardiomyopathy (HCM). Positive long-term data and upcoming catalysts have fueled recent enthusiasm.

Pipeline Progress Fuels Rally

In March 2026, the company reported encouraging long-term results for sevasemten, showing sustained functional stabilization in Becker muscular dystrophy patients over 3.5 years of follow-up. The data reinforced confidence........

© International Business Times